指南与共识慢阻肺哮喘

改善慢性呼吸系统疾病患者处方药可负担性:美国胸科学会政策声明

Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement.
指南 / 共识 · Am J Respir Crit Care Med · 2018-01-01

美国胸科学会组建多学科委员会,针对慢性呼吸系统疾病患者处方药自付费用高、依从性差的问题,经一年讨论一致建议设立公开资助、政治独立、公正的实体,系统制定循证药品政策建议。该实体旨在确保公平可负担的用药可及性,最大化药品支出价值,支持创新并保留医患选择权。

要点

  • 处方药自付费用导致经济负担、依从性下降和健康结局恶化。
  • 常见肺病缺乏仿制药替代,罕见病药物价格高昂,加剧可及性挑战。
  • 建议设立独立实体制定循证药品政策,优先确保各药物类别基本药物进入Tier 1目录。

核心结论

  • 委员会一致建议设立公开资助、政治独立、公正的实体,系统制定循证药品政策建议,以扩大可负担药物可及性并优化资源利用。

研究设计与样本

  • 美国胸科学会召集多学科委员会,成员包括卫生政策、药物经济学、行为科学和临床护理专家,以及产业和患者代表。
  • 报告及建议经一年面对面、电话和电子讨论迭代制定。

主要发现

  • 处方药自付费用对中低收入慢性病患者造成经济负担,降低用药依从性并恶化健康结局。
  • 常见肺病如哮喘和慢阻肺缺乏仿制药替代,罕见病如囊性纤维化药物价格高昂,加剧可负担性和可及性挑战。
  • 美国面临的可负担性和可及性挑战尤为突出,许多其他国家公民支付更低价格且有更大可及性。

关键数值与推荐

  • 委员会一致推荐设立公开资助、政治独立、公正的实体,系统起草循证药品政策建议。
  • 该实体的目标包括确保公平可负担的处方药可及性、最大化公共和私人药品支出健康价值、支持基于市场经济的创新药物开发、保留医患个性化治疗选择。
  • 立即优先事项是审查证据并就每个药物类别中具有既定临床获益的基本药物进入所有Tier 1目录的必要性提出建议,并提出减少及时仿制药可及性障碍的建议。

临床怎么用

  • 临床医生可关注该政策声明,了解药品可负担性对患者依从性和健康结局的影响。
  • 支持并参与推动基本药物进入Tier 1目录及减少仿制药可及性障碍的政策倡导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mounting evidence indicates that out-of-pocket costs for prescription medications, particularly among low- and middle-income patients with chronic diseases, are imposing financial burden, reducing medication adherence, and worsening health outcomes. This problem is exacerbated by a paucity of generic alternatives for prevalent lung diseases, such as asthma and chronic obstructive pulmonary disease, as well as high-cost medicines for rare diseases, such as cystic fibrosis. Affordability and access challenges are especially salient in the United States, as citizens of many other countries pay lower prices for and have greater access to prescription medications. METHODS: The American Thoracic Society convened a multidisciplinary committee comprising experts in health policy pharmacoeconomics, behavioral sciences, and clinical care, along with individuals providing industry and patient perspectives. The report and its recommendation were iteratively developed over a year of in-person, telephonic, and electronic deliberation. RESULTS: The committee unanimously recommended the establishment of a publicly funded, politically independent, impartial entity to systematically draft evidence-based pharmaceutical policy recommendations. The goal of this entity would be to generate evidence and action steps to ensure people have equitable and affordable access to prescription medications, to maximize the value of public and private pharmaceutical expenditures on health, to support novel drug development within a market-based economy, and to preserve clinician and patient choice regarding personalized treatment. An immediate priority is to examine the evidence and make recommendations regarding the need to have essential medicines with established clinical benefit from each drug class in all Tier 1 formularies and propose recommendations to reduce barriers to timely generic drug availability. CONCLUSIONS: By making explicit, evidence-based recommendations, the entity can support the establishment of coherent national policies that expand access to affordable medications, improve the health of patients with chronic disease, and optimize the use of public and private resources.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Patel MR, Press VG, Gerald LB, et al. Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med. 2018. PMID: 30601674. doi:10.1164/rccm.201810-1865ST

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。